Press Releases

12/18/2024

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager....

12/17/2024

New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device

New decision establishes reimbursement for the clinical use of Tempus ECG-AF, reducing the financial burden of using AI to improve early detection of atrial fibrillation

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the...

12/10/2024

Oncology

Tempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Tempus, a leader in artificial intelligence and precision medicine, today announced four abstracts were accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, which convenes from December 10-13, in San Antonio, Texas. "Presenting our latest research at the San Antonio Breast Cancer Symposium underscores Tempus’ commitment to advancing precision medi...

11/25/2024

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at t...

11/12/2024

EMR Integration

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cl...

11/11/2024

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 pati...

11/08/2024

Tempus Announces Nine Abstracts Accepted For Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. "Presenting our latest research is a vit...

11/07/2024

Product Launch

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

IPS test validation study data will be unveiled at the 2024 SITC Annual Meeting Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians...

11/04/2024

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

CHICAGO, November 4, 2024 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leade...

10/31/2024

Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare

Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago’s premier integrated academic health system, today announced a collaboration that aims to explore the application of artificial intelligence in clinical care and research. The collaboration, which is expected to span across several disease conditions...

NEWS

Media Coverage

Additional Partnerships